The best approach for protecting everyone’s health will require us to provide different vaccines to different people according to need and availability.
With vaccine shortages looming, experts are debating whether it is important to receive two doses or whether it’s better to give one dose to more people and give a second when the supply is better.
Researchers say around 70% of the US needs to get the coronavirus vaccine to stop the pandemic. But questions around the vaccines and regional differences add some uncertainty to that estimate.
Experts from across The Conversation assess the work that’s helped us reach vaccine roll-out, how this could play out, and the risk of vaccine hesitancy.
The development of multiple vaccines against the virus that causes COVID-19 has been hailed as the breakthrough of 2020. But there were many more supporting discoveries that made this possible.
We should applaud drug companies for developing COVID-19 vaccines in record time, but let’s not be under any illusion about the profits that are motivating them.
The vaccines that will first be used to prevent the spread of COVID-19 will have gone through a special approval process with the FDA. but just what is this expedited process?
With COVID-19 vaccine announcements making headlines, non-scientists need to know what clinical trial results mean. Here are some key points to look for in vaccine trial reports.
There is now a third vaccine that prevents COVID-19 infections. It isn’t quite as effective as the other two vaccines but it has advantages that may make it the frontrunner.
Data coming through from phase 3 trials are encouraging. But participants don’t represent the whole community — so we can’t be sure these vaccines will work as well in everyone.
COVID-19 vaccines are at risk of being undermined by vaccine hesitancy. Pharma must take steps to ensure transparency in data monitoring committees and trial data to build public trust in vaccines.